ROTTERDAM, The Netherlands, Dec. 17, 2024 /PRNewswire/ -- Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc. (Nasdaq: EXEL) involving ADU-1805, an innovative anti-SIRPα antibody with the potential to enhance the immune system's ability to combat cancer. Under the terms of the agreement, Exelixis has an exclusive option to license worldwide development and commercialization rights for ADU-1805 and other anti-SIRPα ant ...

A month has gone by since the last earnings report for Exelixis (EXEL) . Shares have added about 10.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Exelixis Beats on Q3 Earnings and Sales, Raises Annual O ...

Exelixis, Inc. (EXEL) announced that its supplemental new drug application (sNDA) for cabozantinib will be discussed at an Oncologic Drugs Advisory Committee (“ODAC”) meeting in March 2025.The sNDA is seeking approval for the drug to treat adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET).Exelixis’ shares have surged 48.9% year to date against the industry’s decline of 7.8%.Image Source: Zacks Investment ResearchDetails of EXEL’s sNDA f ...

Shares of Exelixis, Inc. (EXEL) have surged 25% in a month against the industry’s decline of 4.9%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The outperformance can be attributed to better-than-expected third-quarter results. The company also raised its annual guidance.Exelixis has been a consistent outperformer of late on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.EXEL Outperforms Industry, Sector & S&P 500Image So ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as a complementary indicator to the Zacks Rank, helping investors select stocks with high potential for market outperformance [3][9] Zacks Style Scores - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [5][6][7][8] - Each stock is rated from A to F based on its characteristics, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score identifies stocks that are undervalued based on financial ratios such as P/E, PEG, and Price/Sales [5] Growth Score - The Growth Style Score assesses a company's financial health and future growth potential through metrics like earnings and sales projections [6] Momentum Score - The Momentum Style Score focuses on stocks with favorable price trends, utilizing factors like recent price changes and earnings estimate revisions [7] VGM Score - The VGM Score combines the three Style Scores to provide a comprehensive rating, highlighting stocks with attractive value, growth, and momentum [8] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [10] - A significant number of stocks are rated under the Zacks Rank, with over 800 top-rated options available [11] Stock to Watch: Exelixis (EXEL) - Exelixis, Inc. is an oncology-focused biotechnology company engaged in developing treatments for challenging cancers [15] - EXEL holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of A, with a Value Style Score of B, supported by a forward P/E ratio of 18.46 [16] - Recent upward revisions in earnings estimates indicate a positive outlook, with the Zacks Consensus Estimate rising to $1.93 per share [16] - With strong ratings and scores, EXEL is positioned as a notable investment opportunity [17]

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Z ...

It is not surprising that before any earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap stocks that are of high quality.In this regard, we ran a screener that yielded stocks Amazon.com (AMZN) , Maplebear Inc. (CART) , Exelixis (EXEL) and Doximity (DOCS) as the likely winners on the earnings beat potential.Why Is a Positive Earnings Surprise So Important?Historically, stocks of companies ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the trad ...

Core Viewpoint - Exelixis (EXEL) shows a significantly improving earnings outlook, making it a solid investment choice as analysts continue to raise their earnings estimates for the company [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Exelixis's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, Exelixis is projected to earn $0.46 per share, reflecting a 39.39% increase from the previous year, with a 14.31% rise in the Zacks Consensus Estimate over the last 30 days [4]. - For the full year, the earnings estimate stands at $1.92 per share, representing a 113.33% increase from the prior year, with a 5.73% increase in the consensus estimate due to nine upward revisions against one downward revision [5]. Zacks Rank - Exelixis currently holds a Zacks Rank 2 (Buy), supported by favorable estimate revisions, indicating strong potential for outperformance compared to the S&P 500 [6]. - Historically, Zacks 1 (Strong Buy) and 2 (Buy) ranked stocks have shown significant outperformance, with Zacks 1 stocks averaging a 25% annual return since 2008 [3][6]. Stock Performance - Exelixis shares have increased by 30.3% over the past four weeks, suggesting strong investor confidence in the company's earnings growth prospects [7].